1. Cancer statistics, NHL SEER Fact Sheets. National Cancer Institute, 2012, USNIH.
www.cancer.gov
.
2. Shipp MA, Mauch PM, Harris NL. Non-Hodgkin’s lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 2165–219.
3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman Jr CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.
5. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–43.